{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Pneumonia&page=2",
    "query": {
      "condition": "COVID-19 Pneumonia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Pneumonia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T16:25:35.320Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04480333",
      "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
        "Severe Acute Respiratory Syndrome of Upper Respiratory Tract",
        "Neurodegeneration",
        "Neuroinflammatory Response"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831 - 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: NA-831 - 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.10 mg + 1.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.20 mg + 2.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-15",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480333"
    },
    {
      "nct_id": "NCT04513990",
      "title": "Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Infection"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 257,
      "start_date": "2020-04-09",
      "completion_date": "2023-04-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-22",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04513990"
    },
    {
      "nct_id": "NCT05112874",
      "title": "ImmuneSense™ COVID-19 Cross-Reactivity Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronavirus Disease",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Adaptive Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-15",
      "completion_date": "2023-05-17",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05112874"
    },
    {
      "nct_id": "NCT05235347",
      "title": "Sotrovimab Expanded Access Treatment Protocol (COVID-19)",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Sotrovimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05235347"
    },
    {
      "nct_id": "NCT05975060",
      "title": "A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "XBB.1.5 Vaccine (Booster)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XBB.1.5 Vaccine (single dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 660,
      "start_date": "2023-09-07",
      "completion_date": "2024-05-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975060"
    },
    {
      "nct_id": "NCT04409262",
      "title": "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 649,
      "start_date": "2020-06-16",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409262"
    },
    {
      "nct_id": "NCT04784897",
      "title": "A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Brilacidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SoC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovation Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2021-02-22",
      "completion_date": "2021-07-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 2,
      "location_summary": "Winfield, Illinois • Toledo, Ohio",
      "locations": [
        {
          "city": "Winfield",
          "state": "Illinois"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784897"
    },
    {
      "nct_id": "NCT07123727",
      "title": "A Study to Examine Anktiva for the Treatment of COVID-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long COVID Syndrome",
        "Long Covid 19"
      ],
      "interventions": [
        {
          "name": "Anktiva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-04",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07123727"
    },
    {
      "nct_id": "NCT04482686",
      "title": "Trial of Combination Therapy to Treat COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID",
        "Covid-19",
        "Corona Virus Infection",
        "Coronavirus Infection",
        "Coronavirus-19",
        "SARS-CoV2",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline Hcl",
          "type": "DRUG"
        },
        {
          "name": "Zinc",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin C",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-12-09",
      "completion_date": "2022-07-15",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482686"
    },
    {
      "nct_id": "NCT04778059",
      "title": "Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "2019 Novel Coronavirus Infection",
        "COVID-19 Virus Infection",
        "SARS Coronavirus 2 Infection",
        "SARS-CoV-2 Infection",
        "Respiratory Distress Syndrome, Adult",
        "Adult Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "USB002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Biotest, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-07-27",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-06-10T16:25:35.320Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04778059"
    }
  ]
}